Novo Holdings, the venture capital arm of Novo Nordisk, plans to increase its dealmaking activity in 2024 following the success of the weight-loss drug Wegovy. The fund manager’s CEO, Kasim Kutay, stated that the company expects to do “a fair amount” more deals and to expand by opening a second office in Asia. Novo Holdings will use the significant dividends from Novo Nordisk to execute its strategy of investing half of its capital into the life sciences sector. The company’s principal investment team, which focuses on buyout activity in the life sciences and healthcare sector, will benefit from the cash flows generated by Wegovy. Additionally, Kutay mentioned that Novo Holdings avoids investing in areas already focused on by Novo Nordisk, such as diabetes and obesity, but has invested venture capital in biotech companies active in those areas. The CEO noted that the past year has seen attractive valuations in the biotech sector, which has led to increased activity in the venture space. Novo Holdings is taking advantage of these opportunities to drive its investment strategy.
Revved up: Novo Holdings amplifies dealmaking with Wegovy windfall+
Latest from Blog
VCFA Group Closes $1225M Venture Partners VII Fund
TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in
VCFA Group’s Venture Partners VII Fund Raises $1225 Million
TLDR: VCFA Group closed its latest fund, VCFA Venture Partners VII, with $122.5 million in commitments. The fund focuses on smaller and more complex purchases of later-stage venture capital and growth equity
Revolutionizing Payments: $20M Raised for Stablecoin Network Development
TLDR: 1Money has raised over $20 million in seed funding to develop a stablecoin payments network. The network aims to offer instant transaction confirmation, low-cost fees, multicurrency support, compliance mechanisms, and scalability.
Top AI Trends and Startups Shaping 2025 and Beyond
“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Sand Hill Road: Steve Vassallo’s Early Investment Edge at Foundation Capital
“`html TLDR: Steve Vassallo, a general partner at Foundation Capital, focuses on early-stage investments, often being the first institutional investor for startups. He emphasizes the importance of owning a significant stake in